Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
Rana Abdelnabi, Caroline S. Foo, Dirk Jochmans, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 112

Showing 1-25 of 112 citing articles:

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
Laura Vangeel, Winston Chiu, Steven De Jonghe, et al.
Antiviral Research (2022) Vol. 198, pp. 105252-105252
Open Access | Times Cited: 384
The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19
Qing Hu, Yuan Xiong, Guanghao Zhu, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 144
ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies
Jun Siong Low, Josipa Jerak, M. Alejandra Tortorici, et al.
Science (2022) Vol. 377, Iss. 6607, pp. 735-742
Open Access | Times Cited: 139
The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir
Dirk Jochmans, Liu C, Kim Donckers, et al.
mBio (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 127
The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters
Rana Abdelnabi, Caroline S. Foo, Xin Zhang, et al.
Antiviral Research (2022) Vol. 198, pp. 105253-105253
Open Access | Times Cited: 114
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Cong Sun, Chu Xie, Guo‐Long Bu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 113
Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure–Activity Relationship Insights and Evolution Perspectives
Gabriele La Monica, Alessia Bono, Antonino Lauria, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 12500-12534
Open Access | Times Cited: 99
Accelerating antiviral drug discovery: lessons from COVID-19
Annette von Delft, Matthew D. Hall, Ann D. Kwong, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 7, pp. 585-603
Open Access | Times Cited: 94
Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
Yuan‐Pin Hung, Jen‐Chieh Lee, Chun-Wei Chiu, et al.
Antibiotics (2022) Vol. 11, Iss. 2, pp. 220-220
Open Access | Times Cited: 89
S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters
Michihito Sasaki, Koshiro Tabata, Mai Kishimoto, et al.
Science Translational Medicine (2022) Vol. 15, Iss. 679
Open Access | Times Cited: 75
Inhibition of the main protease of SARS-CoV-2 (Mpro) by repurposing/designing drug-like substances and utilizing nature’s toolbox of bioactive compounds
Io Antonopoulou, Eleftheria Sapountzaki, Ulrika Rova, et al.
Computational and Structural Biotechnology Journal (2022) Vol. 20, pp. 1306-1344
Open Access | Times Cited: 67
In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir
Maki Kiso, Seiya Yamayoshi, Shun Iida, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 39
In the age of Omicron variant: Paxlovid raises new hopes of COVID‐19 recovery
Zhonglei Wang, Liyan Yang
Journal of Medical Virology (2021) Vol. 94, Iss. 5, pp. 1766-1767
Closed Access | Times Cited: 80
Anatomical barriers against SARS-CoV-2 neuroinvasion at vulnerable interfaces visualized in deceased COVID-19 patients
Mona Khan, Marnick Clijsters, Sumin Choi, et al.
Neuron (2022) Vol. 110, Iss. 23, pp. 3919-3935.e6
Open Access | Times Cited: 43
The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitorin vitroand confer resistance to nirmatrelvir
Dirk Jochmans, Liu C, Kim Donckers, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 42
Nirmatrelvir Resistant SARS-CoV-2 Variants with High Fitness in Vitro
Yuyong Zhou, Karen Anbro Gammeltoft, Line A. Ryberg, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 42
The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro
Anna Gidari, Samuele Sabbatini, Elisabetta Schiaroli, et al.
Microorganisms (2022) Vol. 10, Iss. 7, pp. 1475-1475
Open Access | Times Cited: 38
In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir
Maki Kiso, Yuri Furusawa, Ryuta Uraki, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 29
SARS-CoV-2 Mpro Inhibitors: Achieved Diversity, Developing Resistance and Future Strategies
Conrad Fischer, Jenson R. Feys
Future Pharmacology (2023) Vol. 3, Iss. 1, pp. 80-107
Open Access | Times Cited: 24
Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2in vitroandin vivo
Takayuki Kuroda, Haruaki Nobori, Keita Fukao, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. 4, pp. 946-952
Open Access | Times Cited: 23
Air-Liquid interface cultures to model drug delivery through the mucociliary epithelial barrier
Rhianna E. Lee, Boris Reidel, Mark Nelson, et al.
Advanced Drug Delivery Reviews (2023) Vol. 198, pp. 114866-114866
Open Access | Times Cited: 21
An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations
Michael Westberg, Yichi Su, Xinzhi Zou, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 738
Open Access | Times Cited: 12
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Sho Iketani, David D. Ho
Cell chemical biology (2024) Vol. 31, Iss. 4, pp. 632-657
Open Access | Times Cited: 7
New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19
Robert L. Atmar, Natalie Finch
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 8
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top